We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

38 hedge funds and large institutions have $2.67M invested in Oncternal Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less call options, than puts

Call options by funds: $47K | Put options by funds: $54K

24% less funds holding

Funds holding: 50 → 38 (-12)

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

57% less capital invested

Capital invested by funds: $6.23M → $2.67M (-$3.56M)

86% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 14

Holders
38
Holders Change
-12
Holders Change %
-24%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
13
Closed
14
Calls
$47K
Puts
$54K
Net Calls
-$7K
Net Calls Change
-$13K

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$75.2K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$59K
3
RIM
Reliant Investment Management
Tennessee
+$22.1K
4
VKH
Virtu KCG Holdings
New York
+$20.6K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$14.7K

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$221K
2
Bank of America
Bank of America
North Carolina
-$156K
3
PP
Paloma Partners
Connecticut
-$155K
4
AQR Capital Management
AQR Capital Management
Connecticut
-$108K
5
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
-$104K
Name Holding Trade Value Shares
Change 		Change in
Stake
Stifel Financial
26
Stifel Financial
Missouri
$7K -$13.3K -9 -56%
OC
27
Oppenheimer & Co
New York
$7K – – –
Citigroup
28
Citigroup
New York
$6K -$2.95K -2 -25%
BRWM
29
B. Riley Wealth Management
Tennessee
$6K – – –
U
30
UBS
Switzerland
$6K +$4.42K +3 +100%
BJ
31
BlackRock Japan
Japan
$5K – – –
DAM
32
Delta Asset Management
Tennessee
$5K – – –
TDC
33
Thompson Davis & Co
Virginia
$4K – – –
BIM
34
BlackRock Investment Management
Delaware
$3K – – –
Wells Fargo
35
Wells Fargo
California
$3K – – –
TCM
36
TD Capital Management
Tennessee
$2K – – –
TRCT
37
Tower Research Capital (TRC)
New York
$1K +$1.47K +1 New
Manulife (Manufacturers Life Insurance)
38
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2 – – –
PP
39
Paloma Partners
Connecticut
– -$155K -80 Closed
COPPSERS
40
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$104K -54 Closed
LP
41
LMR Partners
United Kingdom
– -$78K -41 Closed
VC
42
Vestor Capital
Illinois
– -$69K -36 Closed
Deutsche Bank
43
Deutsche Bank
Germany
– -$60K -32 Closed
SFM
44
Soros Fund Management
New York
– -$54K -28 Closed
CS
45
Credit Suisse
Switzerland
– -$51K -26 Closed
GCP
46
GSA Capital Partners
United Kingdom
– -$32K -17 Closed
CAN
47
Cetera Advisor Networks
California
– -$31K -16 Closed
SAM
48
Summit Asset Management
Tennessee
– -$24K -12 Closed
Jane Street
49
Jane Street
New York
– -$15K -8 Closed
Creative Planning
50
Creative Planning
Kansas
– -$5K -3 Closed
1
2
3

ONCT Hedge Fund Activity: Q3 2014 in Review

38 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2014, worth a combined $2.67M — down 57% from $6.23M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ONCT and 2 opened new positions — a net loss of 12 holders — while 13 trimmed existing stakes and 8 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $75.2K. The largest seller was Northern Trust, cutting an estimated $221K.

  • 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2014, down from 50 in Q2 2014.
  • Funds reported $2.67M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2014, down 57% quarter-over-quarter.
  • 2 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2014 and 14 closed out, a net change of -12 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2014 was BlackRock Institutional Trust, an estimated $75.2K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2014 was Northern Trust, an estimated $221K sold.

Based on aggregated 13F filings for Q3 2014.